Diesel Exhaust Induces Glucocorticoid Resistance
University of British Columbia
30 participants
Dec 1, 2018
INTERVENTIONAL
Conditions
Summary
The investigators are studying the effects of exposure to diesel exhaust on lung inflammation in the presence and absence of an inhaled corticosteroid. Although data is mixed, studies show that asthmatics have increased lung inflammation and worse symptoms during periods of higher air pollution despite taking their anti-inflammatory corticosteroid medication. One possible reason is that air pollution exposure may decrease the ability of corticosteroids to combat inflammation. To test this volunteers will inhale either a placebo or a corticosteroid, before sitting in an exposure booth for 2 hours breathing either filtered air or diluted diesel exhaust. Samples will be collected before and after exposure to analyze the effects of budesonide and diesel exhaust exposure.
Eligibility
Inclusion Criteria2
- Aged 19-49
- Have physician-diagnosed asthma confirmed by the study physician examination, spirometry, methacholine challenge provocative concentration causing a 20% fall (PC20) of \<16 mg/mL, and questionnaires during a screening visit
Exclusion Criteria10
- Smoking of any kind (0.5 pack-years ever, or any current) or use of vape/vaporizing devices
- Regular anti-histamine, NSAID, corticosteroid or other controller medication use
- Pregnancy or breastfeeding
- Methacholine PC20 \>16
- Relevant cardiac condition or arrhythmia
- Body mass index of \>35
- Currently participating in another study that may interfere with this study
- Use of either inhaled or oral corticosteroids in preceding 6 months
- Substantial comorbidities on study physician's examination or other concerns
- Surgery scheduled before anticipated study completion
Interventions
Inhalation of air through a Turbuhaler that contains no medication, as a control.
1.6mg of budesonide from a Turbuhaler.
Exposure to HEPA filtered air, as a control.
Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03615742